Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for...

In the closing of the recent trading day, Boston Scientific (BSX) stood at $82.94, denoting a -0.14% change from the preceding trading day.

Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced...